From Developability Assessment to Clinical Translation: Enabling Poorly Soluble Drug Candidates with the SprāSol® Platform
How a formulation platform carries poorly soluble and complex drug candidates from early developability assessment through to the clinic.
The fifth episode of NAPPA Healthcare & Biopharma Insights turns to a problem that quietly ends many otherwise promising programs: poor solubility. A candidate that cannot be delivered at a useful exposure never gets to show what it can do, and the decisions that determine this are made early, in developability assessment, well before the clinic.
Dr. Zeren Wang, Co-founder, Chairman and Chief Scientific Officer of Pharmacin, presents the SprāSol® platform for poorly soluble and complex drug candidates. The hour follows the path from early developability assessment to clinical translation: what to assess, when, and how a formulation platform changes what is possible for a difficult molecule.
The session is open to NAPPA members, partners, and qualified industry guests. Register below to receive Zoom join details.
Key topics.
- ✓ The SprāSol® platform for poorly soluble and complex drug candidates
- ✓ Developability assessment early in a program
- ✓ Carrying a candidate from assessment to clinical translation
- ✓ Where solubility decides whether a candidate advances
See how SprāSol® approaches poorly soluble and complex drug candidates.
Learn what a developability assessment looks for before a program commits.
Follow the path from early assessment to clinical translation.
Understand where poor solubility stalls candidates, and what can be done about it.
Reserve your seat.
Registration is free for NAPPA members and qualified industry guests. Join details will be sent to your email immediately after registering.